Real world prescription trends of methotrexate for psoriasis in Argentina: results of a national survey

Abstract

A wide heterogeneity in the prescribing profile of MTX for the treatment of psoriasis was observed among Argentinean dermatologists. Suboptimal MTX use was identified in the majority of the prescribers.

Unmet needs in the management of psoriasis in Latin America: a systematic review

“…Mazzuoccoloa et al reported suboptimal use of MTX by 76% of dermatologists in Argentina. 32 Comparable results were found in Holland, where 11% of dermatologists were not well-informed about guidelines. Although 80% of Dutch dermatologists use MTX in clinical practice, only 52% adhere to treatment guidelines when prescribing it.…”

“…Mazzuoccoloa et al conducted a survey on the use of MTX for Pso treatment among Argentinian dermatologists (n = 221). 32 They found that two-thirds of dermatologists included the PPD test and/or a chest X-Ray in their pretreatment work-up. Half of them expected a clinically significant response between weeks 4 and 6 of MTX treatment, 44% between weeks 8 and 12, and 6% after 12 weeks.…”

“…The only variable associated with suboptimal MTX use was the prescriber’s perception of its ineffectiveness (OR = 2.29; 95% CI 1.05–5.00, p = 0.037). 32 …”

“… 74 This may also account for the high rates of positive pre-IMB tuberculosis screening tests reported in Argentina. 32 …”

Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey

“…3 Surveys of international practice have highlighted heterogeneity in the prescription of methotrexate for this indication. 4,5 Herein, we evaluate the modalities of methotrexate prescription for moderate to severe psoriasis by dermatologists in France.…”